Streetbeat News

Products Services

BCRX

BioCryst Pharmaceuticals announced that the Public Health Institute of Chile has approved its oral drug ORLADEYO for the prevention of hereditary angioedema attacks. This approval expands the drug's market reach.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:05 am

HEPA

Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' trial achieved primary and secondary endpoints, showing improvements in liver function and key NASH biomarkers. The results reinforce rencofilstat's antifibrotic mode of action and increase confidence for the ongoing Phase 2b 'ASCEND-NASH' trial.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:03 am

CNTA

The FDA has granted Fast Track designation to Centessa Pharmaceuticals' SerpinPC for the treatment of Hemophilia B. This designation will expedite the development and review process for the drug.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 11:03 am

ALB

F

Albemarle Corporation (ALB) has signed a new five-year agreement with Ford Motor Company (F) to supply battery-grade lithium hydroxide, supporting Ford's electric vehicle (EV) production growth plans.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:52 am

F

GM

TSLA

Tesla has shared a two-minute video on its Tesla Asia Twitter handle, marking a potential foray into traditional advertising. The video features a Model 3 owner highlighting various features of the car. Tesla's advertising budget has been significantly lower compared to other automakers like Ford and General Motors.

Portfolio Pulse from Anan Ashraf

May 22, 2023 | 10:52 am

KRTX

Karuna Therapeutics (NASDAQ:KRTX) will present data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating KarXT in schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting from May 30 to June 2, 2023.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:36 am

RVPH

Reviva Pharmaceuticals (NASDAQ:RVPH) presented promising clinical pharmacology and safety studies data on brilaroxazine at the ASPET 2023 annual meeting. Brilaroxazine is currently in phase 3 clinical trials for schizophrenia, with topline data expected mid-year.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:35 am

AULT

BNMV

Ault Alliance and BitNile Metaverse have launched online roulette as a social gaming feature on their platform, expanding their offerings and potentially attracting more users.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:34 am

F

EnergySource Minerals (ESM) has announced a binding lithium supply contract with Ford Motor Company. ESM is a leader in the domestic production of sustainably produced lithium, a key component in electric vehicle (EV) batteries.

Portfolio Pulse from Charles Gross

May 22, 2023 | 10:32 am